1. Home
  2. MGNI vs RXRX Comparison

MGNI vs RXRX Comparison

Compare MGNI & RXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGNI
  • RXRX
  • Stock Information
  • Founded
  • MGNI 2007
  • RXRX 2013
  • Country
  • MGNI United States
  • RXRX United States
  • Employees
  • MGNI N/A
  • RXRX N/A
  • Industry
  • MGNI Computer Software: Programming Data Processing
  • RXRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MGNI Technology
  • RXRX Health Care
  • Exchange
  • MGNI Nasdaq
  • RXRX Nasdaq
  • Market Cap
  • MGNI 1.7B
  • RXRX 2.0B
  • IPO Year
  • MGNI N/A
  • RXRX 2021
  • Fundamental
  • Price
  • MGNI $15.87
  • RXRX $6.18
  • Analyst Decision
  • MGNI Strong Buy
  • RXRX Buy
  • Analyst Count
  • MGNI 12
  • RXRX 6
  • Target Price
  • MGNI $17.05
  • RXRX $9.40
  • AVG Volume (30 Days)
  • MGNI 2.2M
  • RXRX 5.5M
  • Earning Date
  • MGNI 11-07-2024
  • RXRX 11-06-2024
  • Dividend Yield
  • MGNI N/A
  • RXRX N/A
  • EPS Growth
  • MGNI N/A
  • RXRX N/A
  • EPS
  • MGNI 0.12
  • RXRX N/A
  • Revenue
  • MGNI $661,134,000.00
  • RXRX $65,184,000.00
  • Revenue This Year
  • MGNI $0.39
  • RXRX $50.69
  • Revenue Next Year
  • MGNI $10.90
  • RXRX $40.10
  • P/E Ratio
  • MGNI $133.24
  • RXRX N/A
  • Revenue Growth
  • MGNI 8.71
  • RXRX 37.64
  • 52 Week Low
  • MGNI $7.61
  • RXRX $5.89
  • 52 Week High
  • MGNI $17.00
  • RXRX $15.74
  • Technical
  • Relative Strength Index (RSI)
  • MGNI 77.56
  • RXRX 41.15
  • Support Level
  • MGNI $12.42
  • RXRX $6.68
  • Resistance Level
  • MGNI $17.00
  • RXRX $8.49
  • Average True Range (ATR)
  • MGNI 0.72
  • RXRX 0.51
  • MACD
  • MGNI 0.50
  • RXRX -0.02
  • Stochastic Oscillator
  • MGNI 90.24
  • RXRX 1.07

About MGNI Magnite Inc.

Magnite is one of the largest supply-side platform providers, or SSP, in online advertising. The firm was previously named The Rubicon Project (an online ad exchange) and became Magnite after merging with Telaria (an SSP focused mainly on streaming video providers) in 2020. The firm also purchased another of the leading SSPs within the CTV market, SpotX, in 2021 for $1.2 billion, cementing its long-term focus on grabbing market share in this area. The firm generates nearly 45% of its revenue from the programmatic sale of CTV ad inventory, 35% from mobile online sites and apps, and the remaining from websites accessed via computer.

About RXRX Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Share on Social Networks: